Spotlight On Amniotic Membrane Extract Eye Drops (Amed): A Systematic Review Of The Literature
Published 2023 - 41st Congress of the ESCRS
Reference: PO0793 | Type: Free paper | DOI: 10.82333/hrng-3k02
Authors: Raphael Kilian* 1 , Erika Bonacci 2 , Gerald Schmidinger 3 , Clara Rizzo 2 , Giorgio Marchini 2 , Emilio Pedrotti 2
1University of Verona,Verona,Italy;Medical University of Vienna,Vienna,Austria, 2University of Verona,Verona,Italy, 3Medical University of Vienna,Vienna,Austria
Purpose
To review the literature focusing on the effectiveness of amniotic membrane extract eye drops (AMED) in the treatment of ocular surface diseases.
Setting
Systematic review of the literature.
Methods
Inspection of the PubMed/MEDLINE, Scopus and Central databases was performed until December 15, 2022. Searching two key words, i.e., amniotic membrane extract and amniotic membrane extract eye drops, we identified 1059 studies, 29 of which were selected for a full-text review. Eleven studies met the inclusion criteria, and were analyzed by looking at the rate of clinical improvement, mean time to resolution of corneal staining, adverse events and methods of AMED preparation. Strength of clinical data was graded according to the Oxford Center for Evidence-Based Medicine.
Results
Overall, AMED-compounds were used in 264 eyes of 173 patients. Sixty-seven percent of eyes were treated due to dry eye disease (DED) and the rest due to corneal wound healing disorders (WHD). Three main types of eye drops were described, i.e., lyophilized-, cryopreserved-, and fresh-AMED. Despite the methods of outcome-reporting being very heterogeneous, all included studies showed various grades of improvement in both signs and symptoms of affected patients. The overall incidence of ocular side effects was 2.3%.
Conclusions
Despite the quality of evidence being suboptimal, overall, the available literature suggests that AMED is a valuable tool in the treatment of ocular surface disorders.